



## Cancer Prevention and Control CIRB Meeting Agenda

March 24, 2022

---

### I. Continuing Review

**A171601**, A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer (Protocol Version Date 05/29/20)

---

### II. Continuing Review

**A221805**, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Protocol Version Date 01/12/22)

---

### III. Continuing Review

**NRG-CC009**, Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (Protocol Version Date 01/20/21)

---

### IV. Continuing Review

**S1600**, A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune) (Protocol Version Date 11/09/21)

---

### V. New Study - Initial Review

**S2108CD**, A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy (Protocol Version Date 02/02/22)

---

**VI. New Study - Initial Review**

**UWI20-04-01**, A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer (Protocol Version Date 02/11/22)

---

---

**VII. Amendment**

**URCC-19075**, Multi-center Randomized Controlled Phase II Trial to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN) (Protocol Version Date 02/10/22)

---

---